The University of Rochester Medical Center (URMC) has initiated two clinical trials investigating the efficacy of using convalescent plasma as a therapy for 1) patients who have tested positive for COVID-19 but aren’t hospitalized and 2) individuals who have been exposed to the virus but haven’t yet been infected. With the U.S. Food and Drug Administration’s (FDA) recent declaration of emergency use authorization (EUA) for convalescent plasma, it still leaves a number of lingering questions that only randomized controlled trials can answer.
Covered recently by Phillip Boudreaux writing for Spectrum News, the studies are led by principal investigator Dr. Martin Zand, senior associate dean of clinical research at URMC. Dr. Zand declared, “We think the convalescent plasma treatment might help in these two areas but we don’t know for sure and the only way to know is to have a randomized study where some people receive the plasma and some people don’t and we follow everyone equally.”
The URMC team hopes to zero in on the most effective treatment of the two studies. The two studies can be viewed here.
The Trial Innovation Network
URMC is actually part a study led by Jon Hopkins University and part of the NCATS’ Trial Innovation Network.
About University of Rochester Medical Center
University of Rochester Medical Center is home to over 3,000 people dedicated to scientific research, investigating common and rare illness, from cancer and heart disease to Parkinson’s and pandemic influenza. URMC research has led to therapies that have saved countless lives and improved human health locally, in the region and worldwide.
In just the past five years, URMC has secured over $1.18 billion in biomedical research funding, landing the University in the top 26th percentile of U.S. medical centers in federal research funding. The research operation includes one million square feet of state-of-the-art research space, and value-added support services and shared resources.
Call to Action: Follow the link to learn more about these convalescent plasma studies.